WHERE TO FIND US
• The University of Manchester
Graphene was discovered in Manchester in 2004, and led to Professor Andre Geim and Professor Konstantin Novoselov being awarded the Nobel Prize for Physics in 2010.
The MCRC nanomaterials group brings together bioengineering, pharmacology and nanotechnology and aims to translate fundamental knowledge into advanced, clinically-relevant therapeutics and diagnostics.
We are developing novel, viable and effective therapeutics based on bioengineering and nanotechnology components, used as either the ‘drug’ or the ‘delivery system’. Such components include DNA, RNA, viruses, stem cells, radionuclides, liposomes, carbon nanomaterials and other nanomaterials (quantum dots, fullerenes, carbon nanohorns).
Our researchers are interested in the preclinical development of nanomedicine constructs based on novel nanomaterials of both a synthetic and biological nature, including novel viral and non-viral gene therapy vectors, carbon nanomaterials (fullerenes, nanotubes and grapheme), and embryonic, progenitor, and induced pluripotent stem cells. We are exploring advanced delivery systems for both radio- and chemo-therapeutic agents and assessing the pharmacological and toxicological profile of novel nanomedicines.
We are engineering delivery systems for drugs, cells, proteins, radionuclides and genes towards therapeutic and diagnostic clinical applications. Great emphasis is placed at the interface between in vitro and in vivo studies and how rationally designed and engineered delivery systems can be translated into clinically effective therapeutics and diagnostics.
We have a formal collaboration with Memorial Sloan Kettering Cancer Center in New York City that harnesses the complementary expertise within the two locations.
The Nanomedicine Laboratory is part of the National Graphene Institute.
Chemistry & Chemical Engineering